DHA • DOH • SCFHS • QCHP • MOH — Exam-Ready Clinical Reference • April 2026
| Lesion | Definition | Examples |
|---|---|---|
| Macule | Flat, non-palpable colour change <1 cm | Freckle, early vitiligo, petechiae |
| Papule | Raised, solid lesion <1 cm | Acne, molluscum, lichen planus |
| Plaque | Raised, flat-topped lesion >1 cm | Psoriasis, mycosis fungoides |
| Vesicle | Fluid-filled blister <1 cm | HSV, varicella, dyshidrosis |
| Bulla | Fluid-filled blister >1 cm | Bullous pemphigoid, TEN, burns |
| Pustule | Pus-filled lesion | Acne, folliculitis, impetigo |
| Nodule | Deep, solid, raised >1 cm | Lipoma, cyst, melanoma |
| Wheal | Transient, oedematous papule/plaque (urticaria) | Urticaria, dermographism |
| Component | Max Score |
|---|---|
| Extent (rule of nines %BSA) | 20 |
| Intensity (6 signs × 0–3) | 18 |
| Subjective (itch + sleep loss) | 20 |
| Total max: 103 — <25 mild | 25–50 moderate | >50 severe | |
| Potency | Examples | Use Area |
|---|---|---|
| Mild (Class 1) | Hydrocortisone 0.5–2.5% | Face, groin, axilla, infants — daily use safe |
| Moderate (Class 2) | Clobetasone butyrate 0.05%, Betamethasone valerate 0.025% | Body, limbs — short courses |
| Potent (Class 3) | Betamethasone valerate 0.1%, Mometasone 0.1% | Thick skin areas, scalp — avoid face |
| Very Potent (Class 4) | Clobetasol propionate 0.05% | Palms, soles, lichenified lesions — max 2/52 |
| Class | Examples |
|---|---|
| TNF-α inhibitors | Adalimumab, etanercept, infliximab |
| IL-17 inhibitors | Secukinumab, ixekizumab — rapid clearance |
| IL-23 inhibitors | Guselkumab, risankizumab — durable remission |
| IL-12/23 | Ustekinumab — 12-weekly dosing |
| Parameter | Value | Points |
|---|---|---|
| CRP (mg/L) | ≥150 | 4 |
| WCC (×10⁹/L) | 15–25 / >25 | 1 / 2 |
| Haemoglobin (g/dL) | 11–13.5 / <11 | 1 / 2 |
| Sodium (mmol/L) | <135 | 2 |
| Creatinine (μmol/L) | >141 | 2 |
| Glucose (mmol/L) | >10 | 1 |
| Condition | Organism | Presentation | Treatment |
|---|---|---|---|
| Tinea pedis (athlete's foot) | Trichophyton rubrum | Interdigital maceration, scaling, pruritus | Clotrimazole 1% cream 4/52 or terbinafine 1% cream 1/52 |
| Tinea corporis (ringworm) | T. rubrum, T. tonsurans | Annular scaly plaque with central clearing | Topical terbinafine/clotrimazole; oral for extensive |
| Tinea capitis | T. tonsurans, Microsporum | Scaly scalp patches, broken hairs, lymphadenopathy | Oral griseofulvin or terbinafine 4–8 weeks |
| Onychomycosis | Dermatophytes/Candida | Thickened, discoloured, brittle nails | Oral terbinafine: 250mg daily — 6wks fingernails, 12wks toenails. Monitor LFTs. Amorolfine lacquer adjunct |
| Pityriasis versicolor | Malassezia furfur | Hypo/hyper-pigmented patches on trunk — GCC: very common in heat/sweat | Ketoconazole 2% shampoo applied 5 min daily ×5 days; selenium sulfide. Recurrence common |
Calculated at day 1. 1 point each: age >40, malignancy, HR >120, initial BSA >10%, serum urea >10, glucose >14, bicarbonate <20
| Score | Predicted Mortality |
|---|---|
| 0–1 | 3.2% |
| 2 | 12.1% |
| 3 | 35.3% |
| 4 | 58.3% |
| ≥5 | >90% |
| Letter | Feature | Concern |
|---|---|---|
| A — Asymmetry | Shape | Irregular, asymmetrical |
| B — Border | Edge | Irregular, notched, blurred |
| C — Colour | Pigmentation | Variegated — brown, black, red, white |
| D — Diameter | Size | >6mm (pencil eraser) — but early can be smaller |
| E — Evolution | Change | Growing, changing, new ulceration/bleeding |
| Stage | Description | Key Features |
|---|---|---|
| Stage I | Non-blanchable erythema of intact skin | Skin intact; redness does NOT blanch with 30s pressure; may be darker discolouration in dark skin types |
| Stage II | Partial thickness skin loss | Open shallow wound with red/pink wound bed OR intact/ruptured serum-filled blister. No slough/eschar. |
| Stage III | Full thickness skin loss | Subcutaneous fat visible; slough/eschar may be present; no exposed bone/tendon/muscle. Tunnelling possible. |
| Stage IV | Full thickness tissue loss | Exposed bone, tendon, or muscle; slough/eschar; often tunnelling and undermining. |
| Unstageable | Depth unknown — covered by slough/eschar | Cannot stage until base visible. Stable dry eschar on heels = do NOT remove (natural protection) |
| Deep Tissue | Persistent non-blanchable deep red/maroon/purple discolouration | Intact or non-intact skin; pressure/shear injury to soft tissue. May rapidly deteriorate to Stage III/IV. |
| Subscale | Score Range |
|---|---|
| Sensory perception | 1–4 |
| Moisture | 1–4 |
| Activity | 1–4 |
| Mobility | 1–4 |
| Nutrition | 1–4 |
| Friction & shear | 1–3 |
| Total | 6–23 |
| Dressing Type | Indication | Avoid |
|---|---|---|
| Hydrocolloid | Stage II, minimal-moderate exudate, autolytic debridement | Heavy exudate, infected wounds, Stage III/IV |
| Foam | Moderate-heavy exudate, Stage II/III, cavity (cavity foam) | Dry/necrotic wounds |
| Alginate | Heavy exudate, bleeding wounds (haemostatic), cavity wounds | Dry wounds, Stage I, wounds with sinuses (packing risk) |
| Hydrofibre (Aquacel) | Heavy exudate, infected wounds — forms gel, maintains moisture | Dry wounds |
| Silicone (Mepitel) | Fragile skin, epidermolysis bullosa, donor sites, burns | Heavy exudate (use silicone foam instead) |
| Antimicrobial silver | Infected/critically colonised wounds, chronic non-healing wounds | Clean healing wounds — cytotoxic to fibroblasts if overused |
| Honey (Medihoney) | Infected, malodorous, sloughy wounds — antimicrobial, debriding | Allergy to bee products, heavy exudate alone |
| Feature | Venous | Arterial | Mixed |
|---|---|---|---|
| Location | Medial gaiter (medial malleolus) | Lateral, pressure points, toes | Variable |
| Wound bed | Shallow, exudative, granulating | Deep, pale/grey/necrotic, dry | Mixed features |
| Edges | Irregular, sloping | Punched-out, well-defined | Variable |
| Pain | Dull ache, relieved by elevation | Severe, worse at night/elevation (rest pain) | Mixed |
| Surrounding skin | Lipodermatosclerosis, haemosiderin staining, varicosities | Hairless, shiny, cold, pale/dusky | Mixed |
| ABPI | 0.8–1.3 (normal) | <0.5 (severe ischaemia) | 0.5–0.8 |
| Compression | HIGH compression (40mmHg) — first-line | CONTRAINDICATED if ABPI <0.5 | Modified compression only if ABPI >0.6 |
| Country | Body | Dermatology Relevance |
|---|---|---|
| Dubai | DHA | Wound care competency assessment; dermatology nursing clinical attachment requirements |
| Abu Dhabi | DOH | Scope of practice for nurses in wound care, IV antibiotics |
| Saudi Arabia | SCFHS | Wound care certification program — mandatory for wound care nurses |
| Qatar | QCHP | Nursing licence with specialisation pathway; CPD requirements |
| All GCC | MOH variations | MCQ licensing exams — dermatology questions included |